HUT71310A - Methods and preparations for suppression of proliferative response and induction of tolerance wita polymorphic class ii mhc allopeptides - Google Patents

Methods and preparations for suppression of proliferative response and induction of tolerance wita polymorphic class ii mhc allopeptides

Info

Publication number
HUT71310A
HUT71310A HU9403006A HU9403006A HUT71310A HU T71310 A HUT71310 A HU T71310A HU 9403006 A HU9403006 A HU 9403006A HU 9403006 A HU9403006 A HU 9403006A HU T71310 A HUT71310 A HU T71310A
Authority
HU
Hungary
Prior art keywords
mammal
methods
nonself
wita
suppression
Prior art date
Application number
HU9403006A
Other languages
English (en)
Other versions
HU9403006D0 (en
Inventor
Mohamed Sayegh
Charles B Carpenter
Zhengi Zhang
Howard L Weiner
David A Hafler
Original Assignee
Autoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc filed Critical Autoimmune Inc
Publication of HU9403006D0 publication Critical patent/HU9403006D0/hu
Publication of HUT71310A publication Critical patent/HUT71310A/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
HU9403006A 1992-04-20 1993-04-20 Methods and preparations for suppression of proliferative response and induction of tolerance wita polymorphic class ii mhc allopeptides HUT71310A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87128992A 1992-04-20 1992-04-20
US96177992A 1992-10-15 1992-10-15
US97773792A 1992-11-13 1992-11-13
US08/027,127 US5593698A (en) 1990-10-31 1993-03-05 Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides

Publications (2)

Publication Number Publication Date
HU9403006D0 HU9403006D0 (en) 1994-12-28
HUT71310A true HUT71310A (en) 1995-11-28

Family

ID=27487557

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9403006A HUT71310A (en) 1992-04-20 1993-04-20 Methods and preparations for suppression of proliferative response and induction of tolerance wita polymorphic class ii mhc allopeptides

Country Status (13)

Country Link
US (1) US5593698A (hu)
EP (1) EP0637249B1 (hu)
JP (1) JPH07505892A (hu)
KR (1) KR100275656B1 (hu)
AT (1) ATE205400T1 (hu)
AU (1) AU686101B2 (hu)
BR (1) BR9306345A (hu)
CA (1) CA2118502A1 (hu)
DE (1) DE69330752D1 (hu)
HU (1) HUT71310A (hu)
IL (1) IL105472A (hu)
NO (1) NO943967L (hu)
WO (1) WO1993020842A1 (hu)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US6156306A (en) * 1994-08-17 2000-12-05 Albert Einstein College Of Medicine Of Yeshiva University Pancreatic β-cells for allogeneic transplantation without immunosuppression
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
US7361331B2 (en) * 1996-10-18 2008-04-22 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Plant bioreactors
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
US7348005B2 (en) * 2000-03-15 2008-03-25 Advanced Research And Technology Institute Oral tolerance induction by collagen to prevent allograft rejection
WO2001076617A2 (en) * 2000-03-15 2001-10-18 Advanced Research And Technology Institute Oral tolerance induction by collagen to prevent allograft rejection
EP2295067A1 (en) 2000-05-24 2011-03-16 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services E-selectin for inducing immunotolerance
HU229377B1 (hu) * 2000-08-21 2013-11-28 Apitope Technology Bristol Ltd Tolerogén humán peptidek
US7582313B2 (en) * 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
WO2004045376A2 (en) * 2002-11-15 2004-06-03 The General Hospital Corporation Screening methods to identify treatments for autoimmune disease
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
PL2083856T3 (pl) 2007-08-15 2011-04-29 Circassia Ltd Peptydy do odczulania na alergeny
WO2014124134A1 (en) 2013-02-07 2014-08-14 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
WO2015150492A2 (en) * 2014-04-01 2015-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) An isolated donor mhc-derived peptide and uses thereof
ES2962885T3 (es) 2015-05-15 2024-03-21 Massachusetts Gen Hospital Anticuerpos antagonistas de la superfamilia del receptor del factor de necrosis tumoral
WO2017059132A1 (en) 2015-09-29 2017-04-06 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for bcg therapy
WO2017197331A2 (en) 2016-05-13 2017-11-16 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364762A (en) * 1990-03-21 1994-11-15 Board Of Trustees Of The Leland Stanford Junior University Major histocompatibility complex (MHC) molecules

Also Published As

Publication number Publication date
KR950701228A (ko) 1995-03-23
US5593698A (en) 1997-01-14
BR9306345A (pt) 1998-06-30
EP0637249A4 (en) 1997-01-08
AU4108393A (en) 1993-11-18
IL105472A0 (en) 1993-08-18
NO943967D0 (no) 1994-10-19
WO1993020842A1 (en) 1993-10-28
JPH07505892A (ja) 1995-06-29
EP0637249A1 (en) 1995-02-08
KR100275656B1 (ko) 2000-12-15
IL105472A (en) 1999-06-20
AU686101B2 (en) 1998-02-05
CA2118502A1 (en) 1993-10-28
NO943967L (no) 1994-10-19
ATE205400T1 (de) 2001-09-15
HU9403006D0 (en) 1994-12-28
EP0637249B1 (en) 2001-09-12
DE69330752D1 (de) 2001-10-18

Similar Documents

Publication Publication Date Title
HUT71310A (en) Methods and preparations for suppression of proliferative response and induction of tolerance wita polymorphic class ii mhc allopeptides
Müller et al. Microtubule-depolymerizing agents used in antibody–drug conjugates induce antitumor immunity by stimulation of dendritic cells
PT735893E (pt) Péptidos que se ligam aos alelos pan dr para aumentar a resposta imunitária
KR970706013A (ko) 암에 대해 면역학적 치료활성이 있는 스트레스 단백질-펩티드 복합체 (immunotherapeutic stress protein-peptide complexes against cancer)
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
Pape et al. Characterization of Cytolytic Effector Cells in Peripheral Blood of Healthy Individuals and Cancer Patients: II. Cytotoxicity to Allogeneic or Autochthonous Tumor Cells in Tissue Culture
WO1998033527A3 (en) Cancer immunotherapy with semi-allogeneic cells
GR3034964T3 (en) Lymphocyte activity regulation by hla peptides.
CA2093513A1 (en) Methods and compositions for suppressing allograft rejection in mammals
ES2087163T3 (es) Preparacion antitumoral que comprende intreleucina-2 e histamina, analogo al de las mismas o agonistas de receptor h2.
WO1999003976A3 (en) Method of treating leukocytes, leukocyte compositions and methods of use thereof
Golstein et al. Mouse T cell-mediated cytolysis specifically triggered by cytophilic xenogeneic serum determinants: A caveat for the interpretation of experiments done under “syngeneic” conditions
Oluwole et al. Induction of Peripheral Tolerance by Intrathymic Inoculation of Soluble Alloantigens: Evidence for the Role of Host Antigen-Presenting Cells and Suppresser Cell Mechanism
EP0753005A4 (en) REGULATION OF CYTOTOXIC T LYMPHOCYTE ACTIVITY BY CLASS I MHC PEPTIDES
LaCelle et al. Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy
GR3027668T3 (en) Immunosuppressive compositions
Markmann et al. Modulation of the major histocompatibility complex antigen and the immunogenicity of islet allografts
Schechter et al. Enhancing lymphocytes in spleens of tumor‐bearing mice: affinity chromatography on insolubilized histamine
Toledano et al. Interferon-γ (IFN-γ) and interleukin-2 in the generation of lymphokine-activated killer cell cytotoxicity—IFN-γ-induced suppressive activity
Chen et al. Splenic immune effector and suppressor cells in mice bearing a growing plasmacytoma
Paranjpe et al. Discussion paper: specific paralysis of the antitumor cellular immune response produced by growing tumors studied with a radioisotope footpad assay
HK1021318A1 (en) Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation
Tsokos et al. Concanavalin-induced suppressor cells: characterization on the basis of corticosteroid and radiation sensitivity.
Hassan et al. Corynebacterium parvum stimulation of adherent and non-adherent cytotoxic cells in mice
Röllinghoff et al. Induction of secondary cytotoxic T-lymphocytes in vitro does not require cell proliferation

Legal Events

Date Code Title Description
DFC4 Cancellation of temporary protection due to refusal